P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?

• GALACTÉROS F.,
• VOSKARIDOU E.,
• HABIBI A.,
• CANNAS G.,
• JOSEPH L.,
• LOKO G.,
• DE MONTALEMBERT M.

Affiliations

GALACTÉROS F.

1 Unité des Maladies Génétiques du Globule Rouge, Henri-Mondor university hospital, Créteil, France, Créteil, FRANCE

VOSKARIDOU E.

2 Thalassemia and Sickle Cell Disease Center, « Laiko » General Hospital, Athens, GREECE

HABIBI A.

1 Unité des Maladies Génétiques du Globule Rouge, Henri-Mondor university hospital, Créteil, France, Créteil, FRANCE

CANNAS G.

3 Edouard-Herriot hospital, Lyon, FRANCE

JOSEPH L.

4 Biotherapy department, Necker-Enfants Malades university hospital, Paris, FRANCE

LOKO G.

5 Martinique university hospital, Fort de France, FRANCE

DE MONTALEMBERT M.

6 Pediatrics Department, Necker-Enfants Malades university hospital, Paris, FRANCE